I. Schwaner

发表

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

B. Dörken, H. Oettle, H. Riess, 2011, European journal of cancer.

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.

D. Huhn, H. Oettle, J. Beyer, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).

V. Heinemann, T. Decker, C. Denzlinger, 2020, European journal of cancer.

Modelling of LDL-apheresis: System efficacy and rebound kinetics

I. Schwaner, R. Schwerdtfeger, W. Schwartzkopff, 1988 .

Generation of specific antibodies against the rap1A, rap1B and rap2 small GTP-binding proteins. Analysis of rap and ras proteins in membranes from mammalian cells.

G. Schultz, R. Seifert, R. Frank, 1992, European journal of biochemistry.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).

V. Heinemann, T. Decker, C. Denzlinger, 2022, European journal of cancer.

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal

V. Heinemann, C. Roderburg, A. Kiani, 2022, BMC cancer.

A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study

B. Dörken, H. Oettle, H. Riess, 2008 .

Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy

D. Huhn, W. Siegert, J. Beyer, 1997, Cancer.

Clinical Protocol Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma

P. Albers, T. Sauerbruch, R. Caspari, 2003 .

Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003)

B. Dörken, H. Oettle, H. Riess, 2005 .

Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.

D. Huhn, W. Siegert, H. Heuft, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histamine increases cytosolic Ca2+ in HL-60 promyelocytes predominantly via H2 receptors with an unique agonist/antagonist profile and induces functional differentiation.

R. Seifert, A. Buschauer, A. Höer, 1992, Molecular pharmacology.

The H1 receptor agonist 2-(3-chlorophenyl)histamine activates Gi proteins in HL-60 cells through a mechanism that is independent of known histamine receptor subtypes.

G. Schultz, R. Seifert, S. Offermanns, 1994, Molecular pharmacology.

Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.

P. Albers, T. Sauerbruch, I. Schmidt-Wolf, 2003, Human gene therapy.

Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL.

G. Schultz, R. Seifert, S. Offermanns, 1995, Biochimica et biophysica acta.

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

N. Loman, Jenny C. Chang, Chiun-Sheng Huang, 2022, npj Breast Cancer.

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).

V. Heinemann, T. Decker, C. Denzlinger, 2021, European journal of cancer.

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

B. Dörken, M. Görner, T. Greten, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study

D. Huhn, W. Siegert, I. Schwaner, 1997, Bone Marrow Transplantation.

Comparison of plasmafractionation filters and filtration techniques in the clinical practice of LDL-apheresis.

I. Schwaner, R. Schwerdtfeger, H. Baeyer, 1986, ASAIO transactions.

Differential activation of dibutyryl cAMP-differentiated HL-60 human leukemia cells by chemoattractants.

R. Seifert, S. Offermanns, I. Schwaner, 1994, Biochemical pharmacology.

Lipopeptides activate Gi-proteins in dibutyryl cyclic AMP-differentiated HL-60 cells.

R. Seifert, S. Offermanns, A. Höer, 1993, The Biochemical journal.

Extrakorporale Lipidelimination (LDL-Apherese) in der Behandlung der familiären Hypercholesterinämie: Differentialfiltration versus Dextransulfat-Adsorption - Extracorporeal Lipid Elimination (LDL-apheresis) in the Treatment of Familial Hypercholesterolemia: Differential Filtration versus Dextran Su

W. Schwartzkopff, H. Gräfenhahn, H. v. Baeyer, 1988 .

Membrane low density lipoprotein apheresis in patients with familial hypercholesterolemia

I. Schwaner, R. Schwerdtfeger, F. Kochinke, 1986 .

Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.

D. Huhn, A. Szczepek, S. Serke, 2001, Cytometry.

96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE

N. Loman, Jenny C. Chang, C. Geyer, 2020 .

The prostacyclin analogues, cicaprost and iloprost, increase cytosolic Ca2+ concentration in the human erythroleukemia cell line, HEL, via pertussis toxin-insensitive G-proteins.

G. Schultz, R. Seifert, I. Schwaner, 1992, Eicosanoids.

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts

P. Reichardt, F. Rothmann, M. Grothoff, 2011, British Journal of Cancer.

Receptor-mediated increases in cytosolic Ca2+ in the human erythroleukaemia cell line involve pertussis toxin-sensitive and -insensitive pathways.

G. Schultz, R. Seifert, I. Schwaner, 1992, The Biochemical journal.

Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in Germany

T. Decker, F. Hartmann, M. Welslau, 2023, International journal of cancer.

Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.

V. Heinemann, T. Decker, G. Schuch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Mastoparan may activate GTP hydrolysis by Gi-proteins in HL-60 membranes indirectly through interaction with nucleoside diphosphate kinase.

B. Nürnberg, S. Offermanns, J. Ervens, 1994, The Biochemical journal.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

V. Heinemann, G. Prager, J. Taieb, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

B. Dörken, M. Görner, T. Greten, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy

D. Huhn, W. Siegert, J. Beyer, 1997, Cancer.

A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003

B. Dörken, H. Oettle, H. Riess, 2007 .